SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
Titel:
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
Auteur:
Soria, J.-C. Fülöp, A. Maciel, C. Fischer, J.R. Girotto, G. Lago, S. Smit, E. Ostoros, G. Eberhardt, W.E.E. Lishkovska, P. Lovick, S. Mariani, G. McKeown, A. Kilgour, E. Smith, P. Bowen, K. Kohlmann, A. Carlile, D.J. Jänne, P.A.